BIOMAT Database Logo BIOMAT Database Logo

[Complete remission obtained in a child with relapse of erythroleukemia by low-dose cytosine arabinoside]. 1986

M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao

UI MeSH Term Description Entries
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
[Complete remission achieved by high dose cytosine arabinoside therapy in the 4th relapse of AML].
June 1986, [Rinsho ketsueki] The Japanese journal of clinical hematology,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
[Complete remission obtained in refractory acute lymphocytic leukemia using high-dose cytosine arabinoside combined with low-dose L-asparaginase].
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
Successful Treatment of Congenital Erythroleukemia With Low-Dose Cytosine Arabinoside.
March 2016, Pediatric blood & cancer,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
[Megakaryoblastic leukemia (acute myelofibrosis): complete remission of a case with low-dose cytosine arabinoside].
June 1988, Sangre,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
Hypoplastic acute myeloid leukaemia with 7 years of complete remission by low-dose cytosine arabinoside therapy alone.
July 1995, European journal of haematology,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
[Hypoplastic leukemia achieved long-term remission with low-dose cytosine arabinoside].
January 1995, [Rinsho ketsueki] The Japanese journal of clinical hematology,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
Low-dose cytosine arabinoside-induced remission of lymphoblastic leukemia in a cat.
September 1987, Journal of the American Veterinary Medical Association,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
Low dose cytosine arabinoside used to induce remission in acute myelofibrosis.
October 1984, British journal of haematology,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
Remission induction of ANLL with low dose cytosine arabinoside combined with retinoic acid.
November 1990, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
M Miyazaki, and J Sato, and M Hirose, and T Ninomiya, and M Miyao
[A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
January 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!